Article
Complement gene mutations in children with C3 glomerulopathy: do they affect the response to mycophenolate mofetil?
Pediatric nephrology (Berlin, Germany) - 1 May 2024
Günay Neslihan, Dursun İsmail, Gökçe İbrahim, Akbalık Kara Mehtap, Tekcan Demet, Çiçek Neslihan, Torun Bayram Meral, Koyun Mustafa, Dinçel Nida, Dursun Hasan, Saygılı Seha, Yürük Yıldırım Zeynep Nagehan, Yüksel Selçuk, Dönmez Osman, Yel Sibel, Demircioğlu Kılıç Beltinge, Aydoğ Özlem, Atmış Bahriye, Çaltık Yılmaz Aysun, Bakkaloğlu Sevcan A, Aytaç Mehmet Baha, Taşdemir Mehmet, Kasap Demir Belde, Soylu Alper, Çomak Elif, Kantar Özşahin Aslı, Kaçar Alper, Canpolat Nur, Yılmaz Alev, Girişgen İlknur, Akkoyunlu Kadirye Betül, Alpay Harika, Poyrazoğlu Hakan M
Abstract excerpt
BACKGROUND: C3 glomerulopathy (C3G) is a complement-mediated disease. Although genetic studies are not required for diagnosis, they are valuable for treatment planning and prognosis prediction. The aim of this study is to investigate the clinical phenotypes, kidney survival, and response to mycophenolate mofetil (MMF) treatment in pediatric C3G patients with and without mutations in complement-related genes....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.